 |
PDBsum entry 4bn1
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of v174m mutant of aurora-a kinase
|
|
Structure:
|
 |
Aurora kinase a. Chain: a. Fragment: residues 122-403. Synonym: aurora 2, aurora/ipl1-related kinase 1, ark-1, aurora-relat ed kinase 1, hark1, breast tumor-amplified kinase, serine/threonin e- protein kinase 15, serine/threonine-protein kinase 6, serine/thr eonine-protein kinase aurora-a, aurora-a. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.50Å
|
R-factor:
|
0.195
|
R-free:
|
0.244
|
|
|
Authors:
|
 |
R.A.Bibby,R.Bayliss
|
|
Key ref:
|
 |
F.C.Rowan
et al.
(2013).
Insights into Aurora-A kinase activation using unnatural amino acids incorporated by chemical modification.
Acs Chem Biol,
8,
2184-2191.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
13-May-13
|
Release date:
|
26-Mar-14
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
O14965
(AURKA_HUMAN) -
Aurora kinase A from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
403 a.a.
263 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 3 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Acs Chem Biol
8:2184-2191
(2013)
|
|
PubMed id:
|
|
|
|
|
| |
|
Insights into Aurora-A kinase activation using unnatural amino acids incorporated by chemical modification.
|
|
F.C.Rowan,
M.Richards,
R.A.Bibby,
A.Thompson,
R.Bayliss,
J.Blagg.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Most protein kinases are regulated through activation loop phosphorylation, but
the contributions of individual sites are largely unresolved due to insufficient
control over sample phosphorylation. Aurora-A is a mitotic Ser/Thr protein
kinase that has two regulatory phosphorylation sites on its activation loop,
T287 and T288. While phosphorylation of T288 is known to activate the kinase,
the function of T287 phosphorylation is unclear. We applied site-directed
mutagenesis and selective chemical modification to specifically introduce
bioisosteres for phospho-threonine and other unnatural amino acids at these
positions. Modified Aurora-A proteins were characterized using a biochemical
assay measuring substrate phosphorylation. Replacement of T288 with glutamate
and aspartate weakly stimulated activity. Phospho-cysteine, installed by
chemical synthesis from a corresponding cysteine residue introduced at position
288, showed catalytic activity approaching that of the comparable phospho-serine
protein. Unnatural amino acid residues, with longer side chains, inserted at
position 288 were autophosphorylated and supported substrate phosphorylation.
Aurora-A activity is enhanced by phosphorylation at position 287 alone but is
suppressed when position 288 is also phosphorylated. This is rationalized by
competition between phosphorylated T287 and T288 for a binding site composed of
arginines, based on a structure of Aurora-A in which phospho-T287 occupies this
site. This is, to our knowledge, the first example of a Ser/Thr kinase whose
activity is controlled by the phosphorylation state of adjacent residues in its
activation loop. Overall we demonstrate an approach that combines mutagenesis
and selective chemical modification of selected cysteine residues to investigate
otherwise impenetrable aspects of kinase regulation.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |